Alnylam Pharmaceuticals (MIL:1ALNY) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1ALNY Alnylam Pharmaceuticals Inc MIL:1ALNY
51 GF Score
Price €234.70
GF Value €454.92
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Alnylam Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

MIL:1ALNY vs RVMD, ONC, MRNA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


MIL:1ALNY
51GF Score
Alnylam Pharmaceuticals Inc MIL:1ALNY
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alnylam Pharmaceuticals (MIL:1ALNY) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of €234.70 is trading 48.4% below its estimated GF Value™ of €454.92. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for MIL:1ALNY:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €454.92 vs. price of €234.70 (48.4% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the MIL:1ALNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
51GF Score

Get the complete analysis for MIL:1ALNY

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€234.70
Price
€454.92
GF Value